Camlin Fine Sciences Limited · NSE:CAMLINFINE
Camlin Fine Sciences — Q1 FY2020 Earnings Presentation
25 slides from Camlin Fine Sciences's earnings presentation, Aug 5, 2019
Slide 1: Intimation to stock exchanges under SEBI LODR Regulation 30
5th August, 2019 To, To, BSE Limited , The Manager, 25, P. J. Towers, Listing Department, Dalal Street, National Stock Exchange of India Ltd ., Mumbai - 400 001 Exchange Plaza, Bandra Kurla Complex, Ref: Company Scrip Code: 532834 Bandra (East), Mumbai- 400051 Ref: Symbol: CAMLINFINE I I Series: EQ
Slide 2: Earnings Presentation Q1-FY20
EARNINGS PRESENTATION Q1-FY20
Slide 3: Executive Summary
2 Executive Summary 2 Company Overview Financials FY19 Consolidated (INR Mn) • Camlin Fine Sciences Limited (CFS), formed in 2006 after demerging the Operational fine chemical business from Camlin Ltd., is a vertically integrated company Revenue engaged in research, development, manufacturing, comme
Slide 4: Snapshot
3 Snapshot One of the few Leading Manufacturers of vertically and Antioxidants in the world 3rd largest producer of backward with more than 30 years of Vanillin in the world integrated players experience Strategic move to start Serving more than 80 blends which have higher countries with over Prefer
Slide 5: About the Company
4 About the Company • In 2006, Camlin Fine Sciences Limited (CFS) was formed after de-merging (mirror Total Operational Revenue (INR Mn) shareholding) the fine chemical business from Camlin Ltd. • The Company has over 30 years of experience providing innovative solutions with a 10,000 8,922 competit
Slide 6: Q1-FY20 Financial Overview
5 Q1-FY20 FINANCIAL OVERVIEW
Slide 7: Q1-FY20 Financial & Operational Highlights
6 Q1-FY20 Financial & Operational Highlights Q1-FY20 Financial Highlights (Standalone) : Q1-FY20 Financial Highlights (Consolidated) : • Turnover: INR 1,436 Mn • Turnover: INR 2,601 Mn • EBITDA: INR 97 Mn • EBITDA: INR 355 Mn • EBITDA Margin : 6.75% • EBITDA Margin: 13.65% • Adjusted EBITDA*: INR 10
Slide 8: Q1-FY20 Standalone Income Statement (Ind-AS)
7 Q1-FY20 Standalone Income Statement (Ind-AS) Income Statement (Mn) Q1-FY20 Q1-FY19 Y-o-Y Q4-FY19 Q-o-Q Operational Revenue 1,436 1,079 33.1% 1,715 (16.3)% Total Expenses 1,339** 997 34.3% 1,629 (17.8)% Operational EBITDA 97 82 18.3% 86 12.8% Operational EBITDA Margins (%) 6.75% 7.60% (85) Bps 5.01
Slide 9: Q1-FY20 Consolidated Income Statement (Ind-AS)
8 Q1-FY20 Consolidated Income Statement (Ind-AS) Income Statement (INR Mn) Q1-FY20 Q1-FY19 Y-o-Y Q4-FY19 Q-o-Q Operational Revenue 2,601 1,814 43.4% 2,680 (2.9)% Total Expenses 2,246 1,675 34.1% 2,512 (10.6)% Operational EBITDA 355 139 155.4% 168 111.3% Operational EBITDA Margins (%) 13.65% 7.66% 59
Slide 10: Country Overview
99 COUNTRY OVERVIEW
Slide 11: CFS India
10 CFS India • R&D Centre at Tarapur that has developed many new Diphenol-downstream products • Shelf Life Solutions Development, Testing and Applications Lab at Mumbai that works on testing food formulations and blends for the food, pet food and animal nutrition industries • Provides technical expe
Slide 12: Update on Dahej Project
11 Update on Dahej Project Work / Activities completed • Financial Closing achieved • Basic Process & Mechanical Equipment Engineering • Long lead equipment (process & utility) as well as major equipments – Orders received except Boiler • Civil / Structural Engineering for major non-process building
Slide 13: CFS Mexico
12 CFS Mexico • Acquire 65% stake in Dresen Quimica SAPI De CV, Mexico in May 2016 • Primarily manufactures Blends and Additives • Key customer segments: Oil, Poultry, Diary, Rendering, Aqua, Pet food, Swine, Vitamin Cuba Mexico city Pre-mix Republic of • Total Market size is ~USD 200 Mn and CFS Mex
Slide 14: CFS Europe
13 CFS Europe Performance Chemicals • Acquired the manufacturing facility at Ravenna, Italy in 2011, which provides captive requirements of key raw materials i.e. Hydroquinone and Catechol • Capacity utilization achieved at 95% in FY19 • Considerable growth in EBITDA Margins & Profits due to favoura
Slide 15: CFS Brazil
14 CFS Brazil Shelf Life Solutions • Formed in 2013 for Blends and the production started in 2015 • Has an application lab in Indaiatuba – Brazil for customizing blends for Shelf-life Extension Solutions. • Handles distribution of bulk antioxidants and vanillin. Indaiatuba, Brazil • Key customer seg
Slide 16: CFS Wanglong
15 CFS Wanglong • CFS along with CFS Europe acquired 51% stake in Ningbo Wanglong Flavours in 2017 which had an operational plant since 2011 • This acquisition makes CFS the 3rd largest producer of Vanillin • Located in Grade 1 Industrial zone in the city of Yuyao Zhejiang Province, China. • It manu
Slide 17: CFS North America
16 CFS North America Shelf Life Solutions • Formed in October 2015 as a wholly owned subsidiary Market focus • Food - Bulk oils (synthetic antioxidants), Meat & poultry (natural antioxidants) Iowa, USA • Pet food - Rendering for pet food (natural antioxidants), Rendering for animal feed (synthetic a
Slide 18: Historical Financial Overview
17 HISTORICAL FINANCIAL OVERVIEW
Slide 19: Standalone Income Statement
18 Standalone Income Statement Particulars (INR Mn) FY16 FY17* FY18* FY19* Q1-FY20* Operational Income 4,227 3,376 4,050 5,481 1,436 Total Expenses 3,553 3,156 3,996 5,153 1,339 EBITDA 674 220 54 328 97 EBITDA Margin 15.94% 6.52% 1.33% 5.98% 6.75% Depreciation 101 116 91 91 28 Finance Cost 218 232 2
Slide 20: Standalone Balance Sheet (IND-As)
19 Standalone Balance Sheet (IND-As) Particulars (INR Mn) FY18 FY19 Particulars (INR Mn) FY18 FY19 EQUITY 3,314 3,474 Non-Current Assets 1,597 2,735 a) Equity Share Capital 121 121 a) Property, Plant and Equipment 683 789 b) Other Equity 3,193 3,353 b) Capital Work In Progress 120 524 c) Non-Control
Slide 21: Consolidated Income Statement
20 Consolidated Income Statement PARTICULARS (INR Mn) FY16 FY17* FY18* FY19* Q1-FY20* Operational Income 5,042 5,469 7,228 8,922 2,601 Total Expenses 4,125 5,187 7,073 8,235 2,246 EBITDA 917 282 155 687 355 EBITDA Margin 18.19% 5.16% 2.14% 7.70% 13.65% Depreciation 171 218 267 290 76 Finance Cost 24
Slide 22: Consolidated Balance Sheet (IND-As)
21 Consolidated Balance Sheet (IND-As) PARTICULARS (INR Mn) FY18 FY19 PARTICULARS (INR Mn) FY18 FY19 EQUITY 4,334 4,303 Non-Current Assets 3,510 4,143 a) Equity Share Capital 121 121 a) Property, Plant and Equipment 2,066 2,086 b) Other Equity 3,591 3,588 b) Capital Work In Progress 129 536 c) Non-C
Slide 23: Consolidated Financial Highlights
22 Consolidated Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margin (%) 10,000 1,200 18.19% 20.00% 8,922 8,000 7,228 900 15.00% 5,469 917 6,000 5,042 600 7.70% 10.00% 4,000 5.16% 300 2.14% 5.00% 2,000 687 282 - - 155 0.00% FY16* FY17 FY18 FY19 FY16* FY17 FY18 FY19 Net D
Slide 24: Disclaimer
23 Disclaimer 23 Camlin Fine Sciences Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in
Slide 25: Thank You
24 Thank You
Camlin Fine Sciences — Q1 FY2020 Earnings Presentation on 6ix